Free Papers
Effect of previous cross-linking treatment on bubble formation and type, intraoperative and postoperative complications rates of deep anterior lamellar keratoplasty for keratoconus
Free Paper Details
First Author: E.Sogutlu Sari TURKEY
Co Author(s): A. Kubaloglu
Abstract Details
Purpose:
To compare bubble type and formation, intraoperative and postoperative complication rates of deep anterior lamellar keratoplasty for keratoconus between the eyes with and without history of previous crosslinking treatment.
Setting:
Balıkesir University Medical Faculty Ophthalmology Department, Dunya Eye Hospital
Methods:
This study is a retrospective and comperative case series. Keratoconus patients who underwent DALK surgery with big-bubble technique between January 2015 to January 2018 were reviewed. Intraoperative outcomes including rate of big-bubble formation and bubble type, number of air injections, rate of micro or macroperforations and conversion to penetreting keratoplasty were recorded. Postoperative complications were also included. Patients data were divided into two groups: with previous CXL (CXL-DALK group:27 eyes) and without previous CXL (DALK group:50 eyes) treatment. All parameters were compared between groups.
Results:
Success of big bubble was 88.9% and 90.00% for CXL-DALK and DALK group, respectively. Type 1 bubble was obtained in 21 eyes (87.5%) in CXL-DALK group and in 40 eyes (88.9%) in DALK group. Type 2 bubble was seen in 4 eyes (12.5%) and 5 eyes (11.1%) in CXL-DALK and DALK group, respectively. Microperforation rates were 11.1% for CXL-DALK group and 10.0% for DALK group. Postoperatively, persistent epithelial defect was most common complication in both groups. There was no statistically significant difference between the groups in terms of any intraoperative findings and postoperative complications (p>0.05).
Conclusions:
Previous CXL treatment is not effect the bubble formation and type of DALK surgery. Additional CXL is not cause a negative impact on the intraoperative and postoperative complication rates of DALK.
Financial Disclosure:
-